GlobalData on MSN5d
GSK’s depemokimab shows promise in Phase III trials for chronic rhinosinusitis
Both trials met their primary endpoints, indicating a significant improvement in patients treated with the drug.
Zacks.com on MSN5d
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal ...
FierceBiotech6d
GSK's depemokimab reduces polyps in phase 3 trials, adding weight to upcoming filing
GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...
pharmaphorum6d
GSK asthma hope depemokimab works in second indication
Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...
The Pharma Letter6d
GSK’s depemokimab scores well in CRSwNP trials
UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...
GSK reports positive results from depemokimab trial
GSK has announced positive results from a phase III trial of its depemokimab treatment for chronic rhinosinusitis with nasal ...
Benzinga.com6d
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
GSK's phase 3 trials ANCHOR-1 and ANCHOR-2 met co-primary endpoints for treating CRSwNP with depemokimab. Adverse event rates were similar between depemokimab and placebo in the trials.
Nasdaq5d
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...